ConductScience.org, home

Gene · 974

CD79B: CD79b molecule

11 sourcesgene-search-2026-11-11-0.1.0

Download JSON
Cite this record

ConductScience Library. CD79B: CD79b molecule. Genes, record 974. Release gene-search-2026-11-11-0.1.0, 11 Nov 2026. https://conductscience.org/library/genes/974

On this page

Gene

Its symbol and name are HGNC's, unless HGNC and NCBI Gene contradict each other.

Symbol
CD79B
HGNC
Name
CD79b molecule
HGNC
NCBI Gene ID
974
NCBI Gene
HGNC ID
HGNC:1699
HGNC
Ensembl
ENSG00000007312
NCBI Gene
Aliases
AGM6, B29, IGB, Ig-beta, Igbeta
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
P40259B-cell antigen receptor complex-associated protein beta chain2296Ensembl, GeneID, HGNC

Source UniProt

Patents223

Patents whose sequence listing holds the protein exactly: the same sequence, by SHA-256, length and CRC-64. A sequence a patent lists is not always one it claims.

PublicationPublishedSEQ ID NOProteinSource
JP 2026097916 A2026-06-16282P40259Espacenet
US 12600781 B22026-04-14435P40259Espacenet
JP 2026503246 A2026-01-2868P40259Espacenet
JP 2026004568 A2026-01-1440632P40259Espacenet
JP 2025183333 A2025-12-1678P40259Espacenet
EP 4650780 A22025-11-1927P40259Espacenet
EP 4642805 A22025-11-0568P40259Espacenet
JP 2025530642 A2025-09-1741P40259Espacenet
JP 2025529142 A2025-09-04837P40259Espacenet
KR 1020250126125 A2025-08-2268P40259Espacenet

1 to 10 of 223

See all 223 patents

Drugs1

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

DrugChEMBL IDMechanismAction
POLATUZUMAB VEDOTINCHEMBL3301582B-cell antigen receptor complex-associated protein beta chain binding agentBINDING AGENT

Source ChEMBL

Trials83

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

TrialDrugPhaseResults first postedSource
NCT07511114POLATUZUMAB VEDOTINPHASE3ClinicalTrials.gov
NCT07502872POLATUZUMAB VEDOTINPHASE2ClinicalTrials.gov
NCT07499271POLATUZUMAB VEDOTINPHASE2ClinicalTrials.gov
NCT07415980POLATUZUMAB VEDOTINPHASE1/PHASE2ClinicalTrials.gov
NCT07398638POLATUZUMAB VEDOTINPHASE1/PHASE2ClinicalTrials.gov
NCT07397832POLATUZUMAB VEDOTINPHASE2ClinicalTrials.gov
NCT07371923POLATUZUMAB VEDOTINPHASE2ClinicalTrials.gov
NCT07231250POLATUZUMAB VEDOTINPHASE2ClinicalTrials.gov
NCT07184788POLATUZUMAB VEDOTINPHASE2ClinicalTrials.gov
NCT07122609POLATUZUMAB VEDOTINPHASE2ClinicalTrials.gov

1 to 10 of 83

See all 83 trials

NIH grants1,879

NIH projects whose papers are about the gene, through NIH's grant-paper links.

ProjectTitleIts papers about the geneNewest fiscal year
P30CA008748Cancer Center Support Grant542025
P30CA016672Cancer Center Support Grant462025
ZIABC011008Oncogenic mechanisms and molecular targets in lymphoma212025
P30CA021765Cancer Center Support Grant (CCSG)142025
ZIAAI000898B Cell Biology92025
ZIABC011007Functional genomic screens for molecular targets in cancer92025
ZIASC000550Lymphoma Disease Discovery and Definition92025
P30CA016520Abramson Cancer Center Support Grant72025
P30CA086862Cancer Center Support Grant72025
P30DK019525University of Pennsylvania Diabetes Research Center72025

1 to 10 of 1,879Source NIH's project files

See all 1,879 nih grants

Papers4,161

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

PMIDFound bySource
42818385PubTator, text miningPubMed
42814177PubTator, text miningPubMed
42761030PubTator, text miningPubMed
42754234PubTator, text miningPubMed
42736562PubTator, text miningPubMed
42730455PubTator, text miningPubMed
42715516PubTator, text miningPubMed
42691510PubTator, text miningPubMed
42620849PubTator, text miningPubMed
42613996PubTator, text miningPubMed

1 to 10 of 4,161

See all 4,161 papers

Sources 11

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNone stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GeneNone named. Public domain as US government information
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/974

GET https://conductscience.org/api/genes/v1/974/patents?page=2